Advertisement
U.S. markets open in 5 hours 25 minutes
  • S&P Futures

    5,107.75
    +4.00 (+0.08%)
     
  • Dow Futures

    39,016.00
    -27.00 (-0.07%)
     
  • Nasdaq Futures

    18,123.25
    +40.50 (+0.22%)
     
  • Russell 2000 Futures

    2,056.70
    -0.60 (-0.03%)
     
  • Crude Oil

    78.18
    -0.08 (-0.10%)
     
  • Gold

    2,047.70
    -7.00 (-0.34%)
     
  • Silver

    22.74
    -0.15 (-0.63%)
     
  • EUR/USD

    1.0814
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    4.2520
    0.0000 (0.00%)
     
  • Vix

    13.29
    -0.11 (-0.82%)
     
  • GBP/USD

    1.2633
    +0.0007 (+0.06%)
     
  • USD/JPY

    150.6440
    +0.6600 (+0.44%)
     
  • Bitcoin USD

    61,932.51
    -905.50 (-1.44%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,664.43
    +34.41 (+0.45%)
     
  • Nikkei 225

    39,910.82
    +744.63 (+1.90%)
     

MiNK Therapeutics Insider Ups Holding During Year

Looking at MiNK Therapeutics, Inc.'s (NASDAQ:INKT ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

View our latest analysis for MiNK Therapeutics

MiNK Therapeutics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Executive Chairman Garo Armen for US$95k worth of shares, at about US$0.95 per share. That means that an insider was happy to buy shares at around the current price of US$1.03. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. Happily, the MiNK Therapeutics insider decided to buy shares at close to current prices. Garo Armen was the only individual insider to buy shares in the last twelve months.

The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership Of MiNK Therapeutics

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that MiNK Therapeutics insiders own 8.2% of the company, worth about US$2.9m. We do generally prefer see higher levels of insider ownership.

What Might The Insider Transactions At MiNK Therapeutics Tell Us?

It doesn't really mean much that no insider has traded MiNK Therapeutics shares in the last quarter. However, our analysis of transactions over the last year is heartening. The transactions are fine but it'd be more encouraging if MiNK Therapeutics insiders bought more shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing MiNK Therapeutics. When we did our research, we found 8 warning signs for MiNK Therapeutics (4 are a bit concerning!) that we believe deserve your full attention.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Advertisement